A review of cost-effectiveness analysis: From theory to clinical practice

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBRANDAO, Sara Michelly Goncalves
dc.contributor.authorROCCA, Hans-Peter Brunner-La
dc.contributor.authorLIMA, Antonio Carlos Pedroso de
dc.contributor.authorBOCCHI, Edimar Alcides
dc.date.accessioned2024-02-15T14:40:13Z
dc.date.available2024-02-15T14:40:13Z
dc.date.issued2023
dc.description.abstractCost-effectiveness analysis has long been practiced; registries date back to the United States of America War Department in 1886. In addition, everyone does intuitive cost-effectiveness analyses in their daily lives. In routine medical care, health economic assessment becomes increasingly important due to progressively limited resources, rising demands, population increases, and continuous therapeutic innovations. The health economic assessment must analyze the outcomes and costs of actions and technologies as objectively as possible to guarantee efficient assessment of novel interventions for Public Health Policy. In other words, it is necessary to determine how much society or patients are willing to or able to pay for novel interventions compared with existing alternatives, given the available resources. In addition, increased cost may displace other health care services already provided in case of fixed budget health care systems. To conduct such analyses, researchers must use standard methodologies and interpretations in light of regional characteristics according to social and economic determinants as well as clinical practice. Such an approach may be essential for transforming the current healthcare system to a value-based model. In this narrative review, concepts of the importance of and some approaches to health economic evaluation in clinical practice will be discussed.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationMEDICINE, v.102, n.42, article ID e35614, 7p, 2023
dc.identifier.doi10.1097/MD.0000000000035614
dc.identifier.eissn1536-5964
dc.identifier.issn0025-7974
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57886
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofMedicine
dc.rightsopenAccesseng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.subjectbootstrapping and health policyeng
dc.subjectcost-effectiveness analysiseng
dc.subjectcost-utility analysiseng
dc.subjecthealth economicseng
dc.subjectQALYeng
dc.subject.othereconomic-evaluationeng
dc.subject.otherconfidence-intervalseng
dc.subject.otherhealtheng
dc.subject.otheruncertaintyeng
dc.subject.wosMedicine, General & Internaleng
dc.titleA review of cost-effectiveness analysis: From theory to clinical practiceeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryHolanda
hcfmusp.affiliation.countryisonl
hcfmusp.author.externalROCCA, Hans-Peter Brunner-La:Maastricht Univ, Dept Cardiol, Heart Failure Clin, Med Ctr, Maastricht, Netherlands
hcfmusp.author.externalLIMA, Antonio Carlos Pedroso de:Univ Sao Paulo, Inst Math & Stat, Dept Stat, Sao Paulo, Brazil
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcSARA MICHELLY GONCALVES BRANDAO
hcfmusp.contributor.author-fmusphcEDIMAR ALCIDES BOCCHI
hcfmusp.description.articlenumbere35614
hcfmusp.description.issue42
hcfmusp.description.volume102
hcfmusp.origemWOS
hcfmusp.origem.pubmed37861539
hcfmusp.origem.scopus2-s2.0-85174749839
hcfmusp.origem.wosWOS:001140501600066
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAttema AE, 2018, PHARMACOECONOMICS, V36, P745, DOI 10.1007/s40273-018-0672-zeng
hcfmusp.relation.referenceBaltussen RMPM, 2002, INT J TECHNOL ASSESS, V18, P112eng
hcfmusp.relation.referenceBodrogi J, 2010, BRIT J PHARMACOL, V159, P1367, DOI 10.1111/j.1476-5381.2009.00550.xeng
hcfmusp.relation.referenceBrasil. Ministerio da Saude. Secretaria de Ciencia Tecnologia e Insumos Estrategicos, 2014, Diretrizes metodologicas: diretriz de avaliacao economicaeng
hcfmusp.relation.referenceBRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206eng
hcfmusp.relation.referenceBriggs A., 2006, Decision Modelling for Health Economic Evaluation, VFirst ed, P256eng
hcfmusp.relation.referenceBriggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-Weng
hcfmusp.relation.referenceBriggs AH, 1999, STAT MED, V18, P3245, DOI 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2eng
hcfmusp.relation.referenceBriongos-Figuero S, 2020, ESC HEART FAIL, V7, P280, DOI 10.1002/ehf2.12548eng
hcfmusp.relation.referenceBuxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.3.CO;2-Neng
hcfmusp.relation.referenceChapko MK, 2009, HEALTH ECON, V18, P1188, DOI 10.1002/hec.1422eng
hcfmusp.relation.referenceCylus J., 2018, Health Systems for Prosperity and Solidarity Policy brief. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policieseng
hcfmusp.relation.referenceDieleman JL, 2017, JAMA-J AM MED ASSOC, V318, P1668, DOI 10.1001/jama.2017.15927eng
hcfmusp.relation.referenceDocherty KF, 2017, EUR HEART J, V38, P338, DOI 10.1093/eurheartj/ehw427eng
hcfmusp.relation.referenceDrummond MF., 2006, Methods for the Economic Evaluation of Health Care Programmes, V3rd ed. Thrid ed, P464eng
hcfmusp.relation.referenceDrummond MF., 1980, Principles of Economic Appraisal in Health Care, P148eng
hcfmusp.relation.referenceFenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903eng
hcfmusp.relation.referenceFonarow GC, 2019, JAMA CARDIOL, V4, P691, DOI 10.1001/jamacardio.2019.1647eng
hcfmusp.relation.referenceGold MR., 1996, COST EFFECTIVENESS H, DOI 10.1093/acprof:oso/9780190492939.001.0001/acprof-9780190492939eng
hcfmusp.relation.referenceBrandao SMG, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0158-zeng
hcfmusp.relation.referenceGray AM., 2010, Applied methods of cost-effectiveness analysis in Healthcareeng
hcfmusp.relation.referenceGreene SJ, 2018, CIRCULATION, V138, P1039, DOI 10.1161/CIRCULATIONAHA.118.034668eng
hcfmusp.relation.referenceGurwitz JH, 2020, JAMA CARDIOL, V5, P247, DOI 10.1001/jamacardio.2019.5233eng
hcfmusp.relation.referenceHutubessy RCW, 2001, HEALTH ECON, V10, P473, DOI 10.1002/hec.614eng
hcfmusp.relation.referenceKhatana SAM, 2019, JAMA CARDIOL, V4, P671, DOI 10.1001/jamacardio.2019.1651eng
hcfmusp.relation.referenceManca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944eng
hcfmusp.relation.referenceMATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230eng
hcfmusp.relation.referenceMccarthy J., 2019, Seven in 10 maintain negative view of U.S. healthcare system: gallup poll social serieseng
hcfmusp.relation.referenceMeltzer MI, 2001, LANCET, V358, P993, DOI 10.1016/S0140-6736(01)06107-4eng
hcfmusp.relation.referenceMooney CZ., 1993, Bootstrapping: a non-parametric approach to statistical inference, VFirst ed, P80eng
hcfmusp.relation.referenceNational Institute for Health and Clinical Excellence, 2013, Guide to the methods of technology appraisaleng
hcfmusp.relation.referenceNeumann PJ, 2000, ANNU REV PUBL HEALTH, V21, P587, DOI 10.1146/annurev.publhealth.21.1.587eng
hcfmusp.relation.referencePapanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150eng
hcfmusp.relation.referenceQuade ES., 1971, A History of Cost-Effectiveness, P1eng
hcfmusp.relation.referenceRichardson G, 2004, HEALTH ECON, V13, P1203, DOI 10.1002/hec.901eng
hcfmusp.relation.referenceSanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195eng
hcfmusp.relation.referenceSimoens S, 2010, INT J ENV RES PUB HE, V7, P1835, DOI 10.3390/ijerph7041835eng
hcfmusp.relation.referenceStevens A, 2003, J PUBLIC HEALTH MED, V25, P98, DOI 10.1093/pubmed/fdg022eng
hcfmusp.relation.referenceTan SS, 2009, EUR J HEALTH ECON, V10, P39, DOI 10.1007/s10198-008-0101-xeng
hcfmusp.relation.referenceThe World Bank Report, International comparison program (ICP)eng
hcfmusp.relation.referenceU. S. Environmental Protection Agency (EPA), 2014, Guidelines for preparing economic analyseseng
hcfmusp.relation.referenceWAKKER P, 1995, HEALTH ECON, V4, P373, DOI 10.1002/hec.4730040503eng
hcfmusp.relation.referenceWhitehead SJ, 2010, BRIT MED BULL, V96, P5, DOI 10.1093/bmb/ldq033eng
hcfmusp.relation.referenceZhao H., 2000, Estimating mean quality adjusted lifetime with censored dataeng
hcfmusp.relation.referenceZhao HW, 1999, BIOMETRICS, V55, P1101, DOI 10.1111/j.0006-341X.1999.01101.xeng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationda561a22-d5bb-4c9e-a394-5350ee0af819
relation.isAuthorOfPublicationb91a2818-f913-410b-afa2-af089f99e39c
relation.isAuthorOfPublication.latestForDiscoveryda561a22-d5bb-4c9e-a394-5350ee0af819
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_BRANDAO_A_review_of_costeffectiveness_analysis_From_theory_to_2023.PDF
Tamanho:
779.07 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11